Continuing the sequence? Towards an economic evaluation of whole genome sequencing for the diagnosis of rare diseases in Scotland
Authors:
Open Access
- 20 August 2021
- journal article
- research article
- Published by Springer Nature in Journal of Community Genetics
- Vol. 13 (5) , 487-501
Abstract
Novel developments in genomic medicine may reduce the length of the diagnostic odyssey for patients with rare diseases. Health providers must thus decide whether to offer genome sequencing for the diagnosis of rare conditions in a routine clinical setting. We estimated the costs of singleton standard genetic testing and trio-based whole genome sequencing (WGS), in the context of the Scottish Genomes Partnership (SGP) study. We also explored what users value about genomic sequencing. Insights from the costing and value assessments will inform a subsequent economic evaluation of genomic medicine in Scotland. An average cost of £1,841 per singleton was estimated for the standard genetic testing pathway, with significant variability between phenotypes. WGS cost £6625 per family trio, but this estimate reflects the use of WGS during the SGP project and large cost savings may be realised if sequencing was scaled up. Patients and families valued (i) the chance of receiving a diagnosis (and the peace of mind and closure that brings); (ii) the information provided by WGS (including implications for family planning and secondary findings); and (iii) contributions to future research. Our costings will be updated to address limitations of the current study for incorporation in budget impact modelling and cost-effectiveness analysis (cost per diagnostic yield). Our insights into the benefits of WGS will guide the development of a discrete choice experiment valuation study. This will inform a user-perspective cost–benefit analysis of genome-wide sequencing, accounting for the broader non-health outcomes. Taken together, our research will inform the long-term strategic development of NHS Scotland clinical genetics testing services, and will be of benefit to others seeking to undertake similar evaluations in different contexts.Keywords
This publication has 44 references indexed in Scilit:
- What can “thematic analysis” offer health and wellbeing researchers?International Journal of Qualitative Studies on Health and Well-being, 2014
- Rare-disease genetics in the era of next-generation sequencing: discovery to translationNature Reviews Genetics, 2013
- Diagnostic odyssey of patients with myotonic dystrophyJournal of Neurology, 2013
- Return of incidental findings in genomic medicine: measuring what patients value—development of an instrument to measure preferences for information from next-generation testing (IMPRINT)Genetics in Medicine, 2013
- The Deciphering Developmental Disorders (DDD) studyDevelopmental Medicine & Child Neurology, 2011
- Valuing the benefit of diagnostic testing for genetic causes of idiopathic developmental disability: willingness to pay from families of affected childrenClinical Genetics, 2009
- Rationalising the ‘irrational’: a think aloud study of discrete choice experiment responsesHealth Economics, 2008
- Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groupsInternational Journal for Quality in Health Care, 2007
- Economics notes: Costing in economic evaluationBMJ, 2000
- Willingness to pay for publicly-provided goodsJournal of Health Economics, 1990